AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14609783
Drug: Intravenous phytonadione
RxNorm normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phytonadione
Trial: 14609783
Drug: Oral phytonadione
RxNorm normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phytonadione
Trial: 11196267
Drug: ICE chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE chemotherapy (ifosfamide, carboplatin, etoposide)
Trial: 1861632
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium fluid (ionized calcium 0 mmol/L)
Trial: 1861632
Drug: Control fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control fluid (ionized calcium 1.25 mmol/L)
Trial: 1861632
Drug: No magnesium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No magnesium fluid (ionized magnesium 0 mmol/L)
Trial: 1861632
Drug: No albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No albumin fluid (albumin 0 g/L)
Trial: 6226601
Drug: Cimetidine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 1 g orally for 28 days
Trial: 31286729
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with hyperbaric oxygen (HBO) therapy, treatment given once every day for 6 courses (5 days on, 2 days off).
Trial: 31286729
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy combined with HBO (control group).
Trial: 26266376
Drug: Sufentanil (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.02 μg/kg/h)
Trial: 26266376
Drug: Sufentanil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plus dexmedetomidine (0.02 μg/kg/h each, Group D1)
Trial: 26266376
Drug: Sufentanil (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.02 μg/kg/h) plus dexmedetomidine (0.04 μg/kg/h, Group D2)
Trial: 24340314
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (PPI-CA) with rabeprazole (20 mg), clarithromycin (500 mg), and amoxicillin (1 g) for 10 days.
Trial: 24340314
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (ST) with amoxicillin (1 g) on days 1 to 5, and metronidazole (500 mg) and clarithromycin (500 mg) on days 6 to 10.
Trial: 22495940
Drug: COMET +
RxNorm normalized name: Cometriq
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: COMET + therapy as usual (TAU)
Trial: 7690165
Drug: Aprotinin (high-dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high-dosage Trasylol scheme)
Trial: 2440683
Drug: aprindine 2
RxNorm normalized name: aprindine
DrugBank: Aprindine (DB01429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprindine 2 mg kg‐1
Trial: 2440683
Drug: sotalol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sotalol 1.5 mg kg‐1
Trial: 2440683
Drug: aprindine 1
RxNorm normalized name: aprindine
DrugBank: Aprindine (DB01429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprindine 1 mg kg‐1 & sotalol 0.75 mg kg‐1
Trial: 8517099
Drug: Lidocaine 10%
RxNorm normalized name: LIDOCAINE 10% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 10% spray
Trial: 27412590
Drug: Bromelain (1,050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain (1,050 mg/day)
Trial: 27412590
Drug: Placebo (starch-filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch-filled capsules)
Trial: 25787199
Drug: 30 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 months of dual antiplatelet therapy (continued thienopyridine)
Trial: 25787199
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of dual antiplatelet therapy (placebo)
Trial: 23279713
Drug: Oral training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral training
Trial: 20339966
Drug: Ramipril (2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5-5 mg/day)
Trial: 10811328
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 20 mg/kg/prednisolone
Trial: 10811328
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 2 mg/kg/prednisolone
Trial: 24930625
Drug: Ramucirumab (10mg/kg)
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab (10mg/kg) + Dacarbazine (1000 mg/m(2)) (Arm A)
Trial: 16299436
Drug: Data presented
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data presented as risk difference for treatment outcome
Trial: 8527621
Drug: Loperamide oxide
RxNorm normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide oxide 0.5 mg
Trial: 7547157
Drug: Loperamide oxide
RxNorm normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide oxide 1 mg
Trial: 2275651
Drug: Midazolam to
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam to supplement local anaesthesia
Trial: 109935
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa) for 3 months after adrenalectomy-oophorectomy
Trial: 109935
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (Control group)
Trial: 109935
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa)
Trial: 29306475
Drug: Darapladib, 160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib, 160mg daily
Trial: 22955245
Drug: Cognitive-behavioral smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral smoking cessation treatment with 8 weeks of open-label nicotine patch treatment
Trial: 18375569
Drug: Oral paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral paliperidone
Trial: 18375569
Drug: Oral paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral paliperidone (doses > 3 mg/day)
Trial: 16649835
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment for 32 weeks
Trial: 9602961
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg twice daily for 1 week
Trial: 2465815
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus combination chemotherapy (cisplatin and vinblastine)
Trial: 2465815
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care (palliative radiation, psychosocial support, analgesics, nutritional support)
Trial: 1728876
Drug: Oral labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral labetalol
Trial: 27786578
Drug: Oral extended
RxNorm normalized name: chlorpheniramine maleate 8 MG / codeine phosphate 54.3 MG 12HR Oral Extended Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended release nifedipine
Trial: 21726495
Drug: Gliclazide 80
RxNorm normalized name: gliclazide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide 80 mg with 240 ml of 20% glucose solution after a 10 h overnight fasting
Trial: 3014770
Drug: Inactivated poliomyelitis
RxNorm normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliomyelitis vaccine (IPV)
Trial: 3014770
Drug: Oral poliomyelitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral poliomyelitis vaccine (OPV)
Trial: 15364319
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with routine GP IIb/IIIa blockade
Trial: 9661556
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with saline for ICB and IM injection of saline (Control group)
Trial: 9661556
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with saline for ICB and IM injection of 2 micrograms/kg clonidine (IM group)
Trial: 7662226
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg verapamil + 10 mg enalapril
Trial: 7662226
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg verapamil + 10 mg enalapril
Trial: 1681558
Drug: Loprazolam 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loprazolam 1 mg
Trial: 2569239
Drug: Preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred treatment (either triazolam or loprazolam)
Trial: 772175
Drug: Bromocriptine (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (26 mg daily for 12 weeks)
Trial: 26468834
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied with GaAlAs, 830 nm wavelength, power of 40 mW, energy of 8.4 J/cm2 dose per spot, applied in 8 treatment sessions at 48-hour intervals
Trial: 29368069
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no laser therapy)
Trial: 23481125
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (250 mg of standardized soy extract corresponding to isoflavone 100 mg/day)
Trial: 20959525
Drug: Aclidinium 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium 200 µg
Trial: 20959525
Drug: Aclidinium 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium 800 µg
Trial: 12005077
Drug: Milk basic
RxNorm normalized name: Milk Basic Protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk basic protein (MBP) 40 mg per day
Trial: 7809577
Drug: Indomethacin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.4 mg/kg body weight as an intravenous bolus followed by continuous infusion of 0.4 mg/kg/h for 6 hours)
Trial: 3292590
Drug: Regulated-breathing method
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regulated-breathing method (treatment)
Trial: 30223773
Drug: Repositioning the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repositioning the R‐DLT into the left main bronchus (Group L)
Trial: 30223773
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of lung collapse during one‐lung ventilation (Group L)
Trial: 30223773
Drug: Bronchial injuries
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchial injuries (Group L)
Trial: 30223773
Drug: Vocal cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocal cord injuries (Group L)
Trial: 20728932
Drug: HEV 239
RxNorm normalized name: Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEV 239 vaccine (30 microg of purified recombinant hepatitis E antigen adsorbed to 0.8 mg aluminium hydroxide suspended in 0.5 mL buffered saline)
Trial: 23887167
Drug: Placebo (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (hepatitis B vaccine)
Trial: 18279190
Drug: Hemospan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemospan (200 to 1000 mL)
Trial: 15834928
Drug: AC+D (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC+D (neoadjuvant chemotherapy with docetaxel)
Trial: 15834928
Drug: AC (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (neoadjuvant chemotherapy without docetaxel)
Trial: 7795834
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of weight loss and reduction of dietary sodium
Trial: 31277537
Drug: Dihuang Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihuang Decoction (DHD), taken orally, one dose each time, twice a week for one year
Trial: 31277537
Drug: Alendronate sodium
RxNorm normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate sodium 70 mg orally once a week for one year
Trial: 31277537
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of BMD, serum beta-CTX, and serum SOST between DHD and alendronate groups after treatment
Trial: 26804967
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 2 (dual route/dual release fixed dose combination tablet)
Trial: 26804967
Drug: Formulation 1
RxNorm normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 1 (testosterone solution for sublingual administration and sildenafil tablet)
Trial: 26804967
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 2
Trial: 26804967
Drug: Formulation 1
RxNorm normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 1
Trial: 23477707
Drug: Ticlopidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine plus Ginkgo Biloba extract (250mg ticlopidine plus 80mg Ginkgo Biloba extract twice daily)
Trial: 23477707
Drug: Ticlopidine (250mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250mg twice daily)
Trial: 24942407
Drug: Clopidogrel (75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75mg daily)
Trial: 17588604
Drug: Propranolol (one-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (one-day dose)
Trial: 10357038
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly ECT
Trial: 8348280
Drug: OM-8980 24
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OM-8980 24 mg
Trial: 8348280
Drug: OM-8980 48
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OM-8980 48 mg
Trial: 8348280
Drug: OM-8980 6
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OM-8980 6 mg
Trial: 3745529
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 800 mg twice a day for 5 days
Trial: 3745529
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage of oral acyclovir 200 mg five times a day
Trial: 19761871
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg b.i.d.)
Trial: 24637998
Drug: Standard combined-modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combined-modality treatment (including IN-RT)
Trial: 21806490
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter with extra‐amniotic saline infusion
Trial: 19089532
Drug: Rebamipide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide (100 mg TID)
Trial: 17200777
Drug: Nadroparin 5750
RxNorm normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 5750 anti‐Xa IU s.c. twice daily
Trial: 10676716
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment
Trial: 11937423
Drug: Antibiotic monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic monotherapy
Trial: 11937423
Drug: Aminoglycoside-containing combination
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycoside-containing combination therapy
Trial: 9701716
Drug: ipsapirone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone (0.3 mg/kg, orally)
Trial: 6841923
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (chlorthalidone 15 mg and clonidine 0.1 mg)
Trial: 29491276
Drug: Passion fruit
RxNorm normalized name: passion fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passion fruit seed extract (5 mg piceatannol)
Trial: 24962549
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant human EGF (rhEGF) cream applied twice daily for six weeks
Trial: 24962549
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (control) applied twice daily for six weeks
Trial: 22424564
Drug: DBS+DOPA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBS+DOPA (both medication and DBS on)
Trial: 22424564
Drug: OFF/OFF (off
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFF/OFF (off medication with DBS switched off)
Trial: 22424564
Drug: DOPA (on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOPA (on medication with DBS off)
Trial: 17460427
Drug: Early intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early intravitreal triamcinolone injection (4 mg/0.1 ml)
Trial: 17460427
Drug: Late intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late intravitreal triamcinolone injection (4 mg/0.1 ml)
Trial: 15234072
Drug: DAG oil
RxNorm normalized name: Daglutril
DrugBank: Daglutril (DB05796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAG oil (0.5 g/kg body weight/day)
Trial: 15234072
Drug: TAG oil
RxNorm normalized name: ProVent SKIN TAG OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAG oil (0.5 g/kg body weight/day)
Trial: 9661552
Drug: i.v. patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. patient-controlled analgesia (PCA) with morphine
Trial: 1792811
Drug: Pimobendan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan (2.5 mg bid or 5 mg)
Trial: 6576203
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose methotrexate (ID-MTX) pulses
Trial: 6576203
Drug: COALL-80 induction
RxNorm normalized name: coal tar / polysorbate 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COALL-80 induction therapy modification
Trial: 30811354
Drug: Tissue adhesive
RxNorm normalized name: Tissue adhesives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue adhesive as an adjunct to standard three-layer closure
Trial: 29772277
Drug: 0.1%‐fluorometholone (FML),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1%‐fluorometholone (FML), 4 drops daily for 22 days
Trial: 29772277
Drug: Polyvinyl‐alcohol (PA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvinyl‐alcohol (PA), 4 drops daily for 22 days
Trial: 26874371
Drug: New lenses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New lenses in new cases with fresh solution (control CLCs)
Trial: 18387160
Drug: Colestimide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestimide (3.0 g/day)
Trial: 17704416
Drug: Lapuleucel-T (APC8024)
RxNorm normalized name: Lapuleucel-t
DrugBank: Lapuleucel-t (DB19117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapuleucel-T (APC8024) infusion at weeks 0, 2, and 4; no specific dosage mentioned.
Trial: 12238277
Drug: Double antibiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double antibiotherapy for 10 to 14 days with a double dose of an anti-secretory drug
Trial: 12238277
Drug: Current regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current regimen (7 days of double-dose anti-secretory drug and 2 antibiotics, followed by usual dose for 3 weeks)
Trial: 9525444
Drug: Fexofenadine 120
RxNorm normalized name: fexofenadine hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 120 mg twice daily
Trial: 23534896
Drug: Fexofenadine 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 240 mg/day
Trial: 9525444
Drug: Fexofenadine 120
RxNorm normalized name: fexofenadine hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 120 mg single dose
Trial: 9525444
Drug: Fexofenadine 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 240 mg single dose